Table 1. Characterisation of clinical material (A) and primary antibodies used for immunohistochemistry (IHC) (B).

(A)
Diagnosis, FIGO	Histopathology	Abbrevation	Number of cases (%)
Normal cervix	Normal cervix	SCE	8 (11.94)
CIN 2	Moderate cervical intraepithelial dysplasia	CIN 2	4 (5.97)
CIN 3	Severe cervical intraepithelial dysplasia	CIN 3	9 (13.43)
	Squamous cervical carcinoma in situ		12 (17.91)
SCC, stage IA1	Microinvasion <3 mm in depth and <7 mm horizontally	MicSCC	7 (10.45)
SCC, stage IA2	Invasion >5 mm in depth or >7 mm horizontally	InvSCC	2 (2.99)
SCC, stage IB1	Visible lesion ≤4 cm in greatest dimension		17 (25.37)
SCC, stage IB2	Visible lesion >4 cm		2 (2.99)
SCC, stage IIA	Without parametrial invasion, but involvimg upper 2/3 of vagina		1 (1.49)
SCC, stage IIB	With parametrial invasion		1 (1.49)
SCC, stage III	Extends to pelvic wall or lower third of vagina		3 (4.48)
Total			66

(B)
Protein	Antibody	Origin	Clone	Epitope detection	Dilution factor	Tissues for positive controls	Manufacturer
ANXA6	Sc-1931	Goat polyclonal	N-19	N-terminus	400	Liver hepatocytes	SantaCruz (SantaCruz, CA, USA)
HSP27	Sc-13132	Mouse monoclonal	F-4	Amino acids 32–108	400	Tonsilla	SantaCruz (SantaCruz, CA, USA)
PRDX2	WH007001	Mouse monoclonal	4E 10-2D2	Amino acids 1–199	100	Tonsilla	Sigma-Aldrich
NCF2	HPA006040	Rabbit polyclonal	PrEST	Full-length	150	Glandular epithelium of colon	Sigma-Aldrich
TPM4	WH000717	Mouse monoclonal	4E4-1D2	Full-length	200	Placenta, decidual tissue	Sigma-Aldrich

Abbreviations: CIN=cervical intraepithelial neoplasia; FIGO=International Federation of Gynecologic Oncology; SCC=squamous cervical cancer; SCE=squamous cervical epithelial.